Human non-small-cell lung cancer (NSCLC) is considered to be a chemotherapy-refractory malignancy. The underlying mechanisms remain rather obscure. The multidrug resistanceassociated protein (MRP), mediating a multidrug resistance (MDR) phenotype, has been reported to be overexpressed in several dru
Expression of multidrug resistance-associated protein (MRP) and its relationship with clinicopathological factors in non-small cell lung cancer
โ Scribed by Jun Hao; Hui Wang; En-hua Wang; Xue-shan Qiu; Qing-chang Li; Yun-peng Liu
- Publisher
- Chinese Anti-Cancer Association
- Year
- 2004
- Tongue
- English
- Weight
- 769 KB
- Volume
- 16
- Category
- Article
- ISSN
- 1000-9604
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
MRP has been identified as another multidrug-resistance (MDR) gene and may be involved in an alternative MDR mechanism in some solid tumors. We investigated the expres- sion of M R P mRNA in multidrug-resistant KB sublines (KB-8-5, KB-CZ, C -W and C A I to), human non-small-cell lung carcinomas (NSC
Resistance to chemotherapy is intrinsically present in most nonsmall-cell lung carcinomas (NSCLC). No parameter has yet been determined to predict the response to chemotherapy. However, MRP1 (multidrug resistance-associated protein) is suspected to play an important role in resistance to treatment.